Samsung Biologics Introduces Advanced Organoids for Drug Screening

• Samsung Biologics has launched Samsung Organoids, a 3D cell culture-based drug screening service to support drug discovery and development.

• The launch expands the company’s capabilities into preclinical research, targeting improved drug candidate analysis and IND filing efficiency.

Samsung Biologics, a South Korea-based contract development and manufacturing organisation (CDMO), has announced the launch of Samsung Organoids, a new drug screening platform designed to support drug discovery and development. The offering marks the company’s strategic entry into the preclinical research space.

Samsung Organoids utilise three-dimensional cell culture systems that closely replicate human organs, enabling more clinically relevant drug response analyses. These models are increasingly recognised for their ability to predict patient-specific outcomes, identify biomarkers, and assess drug efficacy in early-stage development.

The new service is aimed at improving lead selection and streamlining the preclinical process by offering precision screening and data-driven analysis. Samsung Biologics will now offer an extended range of support from target discovery and lead selection to clinical trial planning.

According to the company, this expansion is intended to improve the probability of clinical success and help clients overcome early-stage research challenges. “The latest service launch reflects our unwavering commitment to driving innovation by improving drug success rates and creating new possibilities in personalised medicine,” said John Rim, CEO and President of Samsung Biologics.